{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:25:01Z","timestamp":1791127501560,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.mcna.2019.07.004","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T21:02:30Z","timestamp":1569877350000},"page":"1035-1054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":205,"title":["The Diagnosis and Management of Neurofibromatosis Type 1"],"prefix":"10.1016","volume":"103","author":[{"given":"K. Ina","family":"Ly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"9","key":"10.1016\/j.mcna.2019.07.004_bib2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of neurofibromatosis type 1 in the Finnish population","volume":"20","author":"Kallionpaa","year":"2018","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib3","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and mortality of neurofibromatosis: a total population study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.36793","article-title":"Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues","volume":"167A","author":"Rauen","year":"2015","journal-title":"Am J Med Genet A"},{"issue":"17","key":"10.1016\/j.mcna.2019.07.004_bib5","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","article-title":"Epidemiology of neurofibromatosis type 1","volume":"89","author":"Friedman","year":"1999","journal-title":"Am J Med Genet"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2","volume":"278","author":"Gutmann","year":"1997","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib8","first-page":"172","article-title":"National Institutes of Health consensus development conference statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987","volume":"1","year":"1988","journal-title":"Neurofibromatosis"},{"key":"10.1016\/j.mcna.2019.07.004_bib9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): diagnosis and management","volume":"115","author":"Ferner","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"3 Pt 1","key":"10.1016\/j.mcna.2019.07.004_bib10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1542\/peds.105.3.608","article-title":"Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children","volume":"105","author":"DeBella","year":"2000","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/cge.12904","article-title":"Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1","volume":"91","author":"Wimmer","year":"2017","journal-title":"Clin Genet"},{"issue":"9863","key":"10.1016\/j.mcna.2019.07.004_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.mcna.2019.07.004_bib14","article-title":"Schwannomatosis: a genetic and epidemiologic study","author":"Gareth Evans","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","article-title":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis","volume":"88","author":"Smith","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2019.07.004_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): a clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2017.5464","article-title":"Early genetic diagnosis of neurofibromatosis type 2 from skin plaque plexiform schwannomas in childhood","volume":"154","author":"Castellanos","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archopht.125.3.389","article-title":"Ocular pathologic findings of neurofibromatosis type 2","volume":"125","author":"McLaughlin","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.mcna.2019.07.004_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","article-title":"Clinical features of schwannomatosis: a retrospective analysis of 87 patients","volume":"17","author":"Merker","year":"2012","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.mcna.2019.07.004_bib20","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","article-title":"Diagnostic criteria for schwannomatosis","volume":"64","author":"MacCollin","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.mcna.2019.07.004_bib22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/01.wnl.0000201190.89751.41","article-title":"Increasing the specificity of diagnostic criteria for schwannomatosis","volume":"66","author":"Baser","year":"2006","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.mcna.2019.07.004_bib23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1001\/jama.2009.1663","article-title":"Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome","volume":"302","author":"Messiaen","year":"2009","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mcna.2019.07.004_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2008.065243","article-title":"SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype","volume":"46","author":"Pasmant","year":"2009","journal-title":"J\u00a0Med Genet"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N","article-title":"Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects","volume":"15","author":"Messiaen","year":"2000","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/gcc.2870010107","article-title":"Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17","volume":"1","author":"Skuse","year":"1989","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4","article-title":"Hyperactive Ras as a therapeutic target in neurofibromatosis type 1","volume":"89","author":"Weiss","year":"1999","journal-title":"Am J Med Genet"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0896-6273(92)90270-N","article-title":"The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes","volume":"8","author":"Daston","year":"1992","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.mcna.2019.07.004_bib29","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","article-title":"The clinical and diagnostic implications of mosaicism in the neurofibromatoses","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib30","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1212\/NXG.0000000000000261","article-title":"Independent NF1 mutations underlie cafe-au-lait macule development in a woman with segmental NF1","volume":"4","author":"Freret","year":"2018","journal-title":"Neurol Genet"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jmg.33.1.2","article-title":"Molecular genetics of neurofibromatosis type 1 (NF1)","volume":"33","author":"Shen","year":"1996","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajhg.2017.12.001","article-title":"Genotype-phenotype correlation in NF1: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848","volume":"102","author":"Koczkowska","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-017-1766-y","article-title":"Emerging genotype-phenotype relationships in patients with large NF1 deletions","volume":"136","author":"Kehrer-Sawatzki","year":"2017","journal-title":"Hum Genet"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib34","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1086\/510781","article-title":"An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation","volume":"80","author":"Upadhyaya","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.mcna.2019.07.004_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000327557","article-title":"Neurofibromatosis without neurofibromas: confirmation of a genotype-phenotype correlation and implications for genetic testing","volume":"3","author":"Quintans","year":"2011","journal-title":"Case Rep Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41436-018-0269-0","article-title":"Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation","volume":"21","author":"Koczkowska","year":"2019","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.mcna.2019.07.004_bib37","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/ejhg.2014.243","article-title":"p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas","volume":"23","author":"Pinna","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"10.1016\/j.mcna.2019.07.004_bib38","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/humu.22832","article-title":"High incidence of noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation","volume":"36","author":"Rojnueangnit","year":"2015","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.mcna.2019.07.004_bib40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archdermatol.2009.169","article-title":"Predictive value of cafe au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1","volume":"145","author":"Nunley","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.90.6.924","article-title":"Diagnostic outcome in children with multiple cafe au lait spots","volume":"90","author":"Korf","year":"1992","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/BF01955059","article-title":"Relationship between cafe-au-lait spots as the only symptom and peripheral neurofibromatosis (NF1): a follow-up study","volume":"152","author":"Fois","year":"1993","journal-title":"Eur J Pediatr"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1542\/peds.2007-3364","article-title":"Health supervision for children with neurofibromatosis","volume":"121","author":"Hersh","year":"2008","journal-title":"Pediatrics"},{"issue":"Pt 6","key":"10.1016\/j.mcna.2019.07.004_bib44","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","article-title":"Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales","volume":"111","author":"Huson","year":"1988","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.mcna.2019.07.004_bib45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/jmg.26.11.712","article-title":"A\u00a0genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling","volume":"26","author":"Huson","year":"1989","journal-title":"J\u00a0Med Genet"},{"issue":"2 Supplement 1","key":"10.1016\/j.mcna.2019.07.004_bib46","first-page":"S5","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.mcna.2019.07.004_bib47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Beert","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"10.1016\/j.mcna.2019.07.004_bib48","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ajmg.a.32301","article-title":"The role of steroid hormones in the NF1 phenotype: focus on pregnancy","volume":"146A","author":"Roth","year":"2008","journal-title":"Am J Med Genet A"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib49","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.13966","article-title":"Neurofibromatosis type 1: neurofibromas and sex","volume":"174","author":"Sbidian","year":"2016","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib50","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2340\/00015555-2241","article-title":"Clinical characteristics of pruritus in neurofibromatosis 1","volume":"96","author":"Brenaut","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"10.1016\/j.mcna.2019.07.004_bib51","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archderm.137.11.1421","article-title":"Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases","volume":"137","author":"Wolkenstein","year":"2001","journal-title":"Arch Dermatol"},{"issue":"2 Supplement 1","key":"10.1016\/j.mcna.2019.07.004_bib52","first-page":"S21","article-title":"Considerations for development of therapies for cutaneous neurofibroma","volume":"91","author":"Verma","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-018-0772-z","article-title":"Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study","volume":"13","author":"Cannon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"18","key":"10.1016\/j.mcna.2019.07.004_bib54","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM199105023241807","article-title":"Lisch nodules in neurofibromatosis type 1","volume":"324","author":"Lubs","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib55","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/IAE.0000000000001578","article-title":"Retinal vascular abnormalities in a large cohort of patients affected by neurofibromatosis type 1: a study using optical coherence tomography angiography","volume":"38","author":"Parrozzani","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.mcna.2019.07.004_bib56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib57","doi-asserted-by":"crossref","first-page":"e35711","DOI":"10.1371\/journal.pone.0035711","article-title":"Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis","volume":"7","author":"Plotkin","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib58","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00234-005-0033-4","article-title":"MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1","volume":"48","author":"Mautner","year":"2006","journal-title":"Neuroradiology"},{"issue":"9","key":"10.1016\/j.mcna.2019.07.004_bib59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib60","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1215\/15228517-2008-011","article-title":"Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1","volume":"10","author":"Mautner","year":"2008","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.mcna.2019.07.004_bib61","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.mcna.2019.07.004_bib62","doi-asserted-by":"crossref","unstructured":"Gross A, Wolters P, Baldwin A, et\u00a0al. SPRINT: phase II study of the MEK 1\/2 inhibitor selumetinib (AZD244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): American Society for clinical oncology; 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.10503"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","article-title":"Malignant peripheral nerve sheath tumors","volume":"19","author":"Farid","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-013-1293-1","article-title":"Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1","volume":"116","author":"Nguyen","year":"2014","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/01.wnl.0000168830.79997.13","article-title":"Association between benign and malignant peripheral nerve sheath tumors in NF1","volume":"65","author":"Tucker","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcna.2019.07.004_bib66","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/1096-8628(20000828)93:5<388::AID-AJMG8>3.0.CO;2-#","article-title":"Malignant peripheral nerve sheath tumors in neurofibromatosis 1","volume":"93","author":"King","year":"2000","journal-title":"Am J Med Genet"},{"issue":"5","key":"10.1016\/j.mcna.2019.07.004_bib67","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/374821","article-title":"Elevated risk for MPNST in NF1 microdeletion patients","volume":"72","author":"De Raedt","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib68","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1097\/MPH.0000000000001156","article-title":"Malignant peripheral nerve sheath tumors in neurofibromatosis: impact of family history","volume":"40","author":"Malbari","year":"2018","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.mcna.2019.07.004_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx124","article-title":"Neurofibromatosis type 1-associated MPNST state of the science: outlining a research agenda for the future","volume":"109","author":"Reilly","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<23::AID-AJMG6>3.0.CO;2-#","article-title":"Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis","volume":"89","author":"Woodruff","year":"1999","journal-title":"Am J Med Genet"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib71","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2214\/AJR.09.2724","article-title":"MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas","volume":"194","author":"Wasa","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib72","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/foc.2007.22.6.13","article-title":"Malignant peripheral nerve sheath tumors","volume":"22","author":"Gupta","year":"2007","journal-title":"Neurosurg Focus"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib73","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/neuonc\/noy013","article-title":"The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors","volume":"20","author":"Higham","year":"2018","journal-title":"Neuro Oncol"},{"issue":"7 Suppl 1","key":"10.1016\/j.mcna.2019.07.004_bib74","first-page":"S31","article-title":"Current whole-body MRI applications in the\u00a0neurofibromatoses: NF1, NF2, and schwannomatosis","volume":"87","author":"Ahlawat","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib75","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdm450","article-title":"[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study","volume":"19","author":"Ferner","year":"2008","journal-title":"Ann Oncology"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib76","first-page":"142","article-title":"Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1","volume":"118","author":"Dunn","year":"2013","journal-title":"J\u00a0Neurosurg"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J\u00a0Child Neurol"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1227\/01.NEU.0000298904.63635.2D","article-title":"Brainstem lesions in neurofibromatosis type 1","volume":"61","author":"Ullrich","year":"2007","journal-title":"Neurosurgery"},{"issue":"16","key":"10.1016\/j.mcna.2019.07.004_bib80","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000003881","article-title":"A\u00a0multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1","volume":"88","author":"Mahdi","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcna.2019.07.004_bib81","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00381-009-1024-2","article-title":"Neurofibromatosis type 1 and high-grade tumors of the central nervous system","volume":"26","author":"Rosenfeld","year":"2010","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"10.1016\/j.mcna.2019.07.004_bib82","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/ajmg.a.37622","article-title":"Histologically benign, clinically aggressive: progressive non-optic pathway pilocytic astrocytomas in adults with NF1","volume":"170","author":"Strowd","year":"2016","journal-title":"Am J Med Genet A"},{"issue":"7","key":"10.1016\/j.mcna.2019.07.004_bib83","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","article-title":"The nature and frequency of cognitive deficits in children with neurofibromatosis type 1","volume":"65","author":"Hyman","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mcna.2019.07.004_bib84","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.48.4.1121","article-title":"Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force","volume":"48","author":"North","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib85","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MOP.0b013e32834230ce","article-title":"Orthopaedic aspects of neurofibromatosis: update","volume":"23","author":"Delucia","year":"2011","journal-title":"Curr Opin Pediatr"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib86","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","article-title":"Generalized metabolic bone disease in Neurofibromatosis type I","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib87","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ajmg.a.33189","article-title":"What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers","volume":"152A","author":"Kissil","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1016\/j.mcna.2019.07.004_bib88","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/BPO.0b013e31828121b8","article-title":"Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium","volume":"33","author":"Stevenson","year":"2013","journal-title":"J\u00a0Pediatr Orthop"},{"issue":"10","key":"10.1016\/j.mcna.2019.07.004_bib89","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ajmg.a.33045","article-title":"Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options","volume":"149A","author":"Elefteriou","year":"2009","journal-title":"Am J Med Genet A"},{"issue":"5","key":"10.1016\/j.mcna.2019.07.004_bib90","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/0883073812448531","article-title":"Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1","volume":"28","author":"Kaas","year":"2013","journal-title":"J\u00a0Child Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2019.07.004_bib91","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","article-title":"A\u00a0prospective study of neurofibromatosis type 1 cancer incidence in the UK","volume":"95","author":"Walker","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2019.07.004_bib92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.mcna.2019.07.004_bib93","first-page":"531","article-title":"Increased risk of breast cancer in neurofibromatosis type 1: current insights","volume":"9","author":"Howell","year":"2017","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.mcna.2019.07.004_bib94","doi-asserted-by":"crossref","first-page":"e5908","DOI":"10.1136\/bmj.e5908","article-title":"Preimplantation genetic testing","volume":"345","author":"Brezina","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.mcna.2019.07.004_bib95","doi-asserted-by":"crossref","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"AAP COUNCIL ON GENETICS, AAP AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712519300744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712519300744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T10:00:58Z","timestamp":1706004058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712519300744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0025712519300744"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2019.07.004","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Diagnosis and Management of Neurofibromatosis Type 1","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2019.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}